



HHS Public Access

Author manuscript

Int J Expo Toxicol. Author manuscript; available in PMC 2026 February 10.

Published in final edited form as:

Int J Expo Toxicol. 2026 ; 1(1): .

Exposomics: From Daily-Life Exposure Monitoring to Precision Prevention

Aristides Tsatsakis^{1,2,3,*}, Dimosthenis A. Sarigiannis^{4,5,6,7}, Michael Aschner⁸, Ramin Rezaee⁹

¹Center of Toxicology Science & Research, Division of Morphology, Medical School, University of Crete, Voutes Campus, 71003 Heraklion, Greece

²Faculty of Health Sciences and Human Development, Universidad ECOTEC, Samborondón 13.5 Km, Samborondón EC092302, Ecuador

³I. M. Sechenov First Moscow State Medical University, Moscow 119435, Russia

⁴National Hellenic Research Foundation, 48 Vassileos Constantinou Avenue, 11635 Athens, Greece

⁵Environmental Engineering Laboratory, Department of Chemical Engineering, Aristotle University of Thessaloniki, University Campus, 54124 Thessaloniki, Greece

⁶HERACLES Research Center on the Exposome and Health, Center for Interdisciplinary Research and Innovation, Balkan Center, 57001 Thessaloniki, Greece

⁷Research Center on Complex Risk and Data Analysis, University School for Advanced Studies IUSS, 27100 Pavia, Italy

⁸Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA

⁹Applied Biomedical Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad 91778-99191, Iran

As founding editors, we are pleased to announce the launch of the *International Journal of Exposome and Toxicology (IJET)*, a dedicated forum for research at the interface of exposure science, exposomics and mechanistic toxicology, with a clear focus on real-life exposure scenarios.

The exposome was introduced to capture the totality of environmental, occupational, lifestyle and social exposures across the life course, starting from preconception and

This is an open access article under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

*Correspondence: aristsatsakis@gmail.com.

Conflicts of Interest

Aristides Tsatsakis serves as the Editor-in-Chief. Dimosthenis A. Sarigiannis, Michael Aschner and Ramin Rezaee serve as Associate Editors. They had no involvement in the peer review of this paper and had no access to information regarding its peer-review process. Full responsibility for the editorial process of this paper was delegated to another editor of the journal.

Use of AI and AI-Assisted Technologies
No AI tools were utilized for this paper.

continuing throughout life. In our work, we have advocated for an operational view of the exposome as a time-resolved “exposure type”—the vector of external and internal exposures that, together with the genotype, shapes the phenotype and ultimately the risk of disease, and can serve as a practical tool for improved health risk assessment [1]. This perspective reframes the classic “nature versus nurture” debate into a systems paradigm of dynamic interactions between environmental exposures, endogenous processes and genetic expression [2,3]. Twin studies and exposure science also support the central role of environmental determinants in health outcomes [4,5].

Exposomics provides the methodological toolbox to characterise both the external and the internal exposome. Beyond environmental monitoring, it integrates human biomonitoring, refined exposure assessment (multi-route/multi-pathway), internal dosimetry and physiologically based biokinetic (PBPK/PBTK) modelling with multi-omics profiling (e.g., metabolomics, transcriptomics, epigenomics and proteomics) and exposome-wide association studies (ExWAS). When these data streams are analysed jointly, they can reduce exposure misclassification, strengthen causal inference and help translate exposure–response relationships into targeted prevention strategies and policy-relevant risk management [6]. The HERACLES project illustrates this approach by combining environmental measurements, biomonitoring, omics and clinical endpoints to investigate child neurodevelopment in communities affected by chronic pollution while accounting for socioeconomic and lifestyle modifiers [2,3].

Among the integrative biomarkers relevant to the internal exposome, telomere length and dynamics are increasingly explored as indicators of cumulative biological stress and ageing. Changes in telomere biology may reflect the combined imprint of chronic low-dose exposures acting through oxidative stress, inflammation, mitochondrial dysfunction and epigenetic regulation, and may therefore support exposome-based risk stratification [7].

In real life, humans are exposed daily to complex mixtures of chemicals and non-chemical stressors through air, water, diet and the built environment. Yet traditional risk assessment still often relies on single-chemical paradigms and high-dose testing, potentially overlooking mixture effects (additive, antagonistic, synergistic or supra-additive) and susceptible subgroups [8,9]. The Real-Life Risk Simulation (RLRS) approach has been proposed to bridge this gap by aligning exposure scenarios, mechanistic evidence and modelling to better support cumulative risk assessment and decision-making [6,10].

Progress in this field depends on integration: combining high-quality epidemiology with innovative experimental systems, new approach methodologies and *in silico* tools, while explicitly linking external exposure metrics to biologically effective doses and toxicity pathway perturbations. Such evidence integration is essential for moving from associations to causality and for ensuring that exposome science meaningfully informs regulation and public health action [6,11].

The *IJET* is established as a gold open access, peer-reviewed journal with the mission of advancing evidence-based toxicological research, with particular emphasis on innovations in single and multiple exposure assessment. By providing an international platform for

interdisciplinary scholarship, *IJET* seeks to elucidate the complex relationships between environmental exposures and biological and health outcomes across the life course. The journal welcomes high-quality original research and authoritative reviews spanning preclinical (*in silico*, *in vitro*, and *in vivo*) as well as clinical investigations in the following areas:

- **Biomonitoring and exposure assessment**
Research using cutting-edge approaches for biomonitoring and exposure science, including targeted and untargeted measurements, high-resolution mass spectrometry, sensors and wearables, geospatial analytics, and human biomonitoring to characterise external exposures and translate them into internal exposure metrics and biologically effective doses.
- **Exposome and ecosystem-health links**
Innovative research linking ecosystem integrity, environmental contamination and human health within One Health/planetary health perspectives, including studies that connect changes in environmental media to the human exposome and health impacts across the life course.
- **Policy and regulation**
Studies aimed at informing policy-making and regulation through exposome-informed evidence, cumulative and mixture risk assessment, and translation of mechanistic and epidemiological findings into decision-relevant metrics.
- **Epidemiological, clinical and experimental toxicology**
Epidemiological, clinical and experimental (*in vivo*, *in vitro* and *in silico*) studies investigating adverse effects of natural and synthetic toxicants, including exposome-wide association designs, vulnerable populations and critical windows of susceptibility.
- **Protective and mitigating effects**
Human, animal and cellular studies reporting protective or mitigating effects (e.g., nutritional, behavioural, pharmacological or technological interventions) against toxic insults, and research on resilience factors that modify exposure–effect relationships.
- **Analytical evaluations and risk assessment**
Analytical studies and risk assessments of human exposure to chemicals via different routes (food, environmental and occupational exposure, pharmaceuticals and consumer products), incorporating internal dosimetry, PBPK/PBTK modelling, real-life risk simulation and explicit treatment of uncertainty and variability.
- **Exposure reduction and mitigation strategies**

Research on the development, evaluation and implementation of strategies to reduce or mitigate exposure to toxic agents at individual, community and population levels, including precision prevention approaches.

- Novel toxicity assessment methods

Studies describing the development, validation or application of innovative toxicity assessment methods and testing strategies, including new approach methodologies (NAMs), high-throughput screening and advanced in vitro models (e.g., organoids and organ-on-chip platforms).
- Mechanistic toxicology

Research aimed at unravelling molecular and cellular mechanisms underlying adverse health impacts of exposures, including pathway perturbations, adverse outcome pathways (AOPs) and systems toxicology approaches.
- Chemicals of emerging concern

Investigations into the toxicological properties, exposure patterns, mixture behaviour and health implications of chemicals of emerging concern (e.g., PFAS, microplastics, nanomaterials and novel consumer-product ingredients).

We strongly encourage authors to provide a clear indication of the real-life relevance of the studied exposure(s): typical concentration ranges, exposure routes, mixture context, and (where possible) biologically effective dose metrics. We also welcome submissions that explicitly discuss implications for risk assessment, regulation and precision prevention in public health.

References

1. Sarigiannis DA The Exposome: A New Tool for Improved Health Risk Assessment. In Management of Emerging Public Health Issues and Risks; Roig B, Weiss K, Thireau V, Eds.; Elsevier: Amsterdam, The Netherlands, 2019; pp 30–45. 10.1016/B978-0-12-813290-6.02002-3.
2. Sarigiannis DA Assessing the Impact of Hazardous Waste on Children’s Health: The Exposome Paradigm. *Environ. Res* 2017, 158, 531–541. 10.1016/j.envres.2017.06.031. [PubMed: 28711809]
3. Sarigiannis DA; Karakitsios SP Addressing Complexity of Health Impact Assessment in Industrially Contaminated Sites via the Exposome Paradigm. *Epidemiol. Prev* 2018, 42, 37–48. 10.19191/EP18.5-6.S1.P037.086. [PubMed: 30322234]
4. Lichtenstein P; Holm NV; Verkasalo PK; et al. Environmental and Heritable Factors in the Causation of Cancer: Analyses of Cohorts of Twins from Sweden, Denmark, and Finland. *N. Engl. J. Med* 2000, 343, 78–85. 10.1056/NEJM200007133430201. [PubMed: 10891514]
5. Rappaport SM; Smith MT Environment and Disease Risks. *Science* 2010, 330, 460–461. 10.1126/science.1192603. [PubMed: 20966241]
6. Sarigiannis D; Karakitsios S; Anesti O; et al. Advancing Translational Exposomics: Bridging Genome, Exposome and Personalized Medicine. *Hum. Genomics* 2025, 19, 48. 10.1186/s40246-025-00761-6. [PubMed: 40307849]
7. Renieri E; Sarigiannis DA; Tsatsakis A S01–01 Exposomics and Telomeres. *Toxicol. Lett* 2025, 411, S14. 10.1016/j.toxlet.2025.07.042.
8. European Food Safety Authority. International Frameworks Dealing with Human Risk Assessment of Combined Exposure to Multiple Chemicals. *EFSA J* 2013, 11, 3313. 10.2903/j.efsa.2013.3313.

9. Tsatsakis AM; Docea AO; Tsitsimpikou C New Challenges in Risk Assessment of Chemicals When Simulating Real Exposure Scenarios. *Food Chem. Toxicol* 2016, 96, 174–176. 10.1016/j.fct.2016.08.011. [PubMed: 27515866]
10. Hernández AF; Docea AO; Goumenou M; et al. Application of Novel Technologies and Mechanistic Data for Risk Assessment under the Real-Life Risk Simulation (RLRS) Approach. *Food Chem. Toxicol* 2020, 137, 111123. 10.1016/j.fct.2020.111123. [PubMed: 31926207]
11. Hernández AF; Tsatsakis AM Human Exposure to Chemical Mixtures: Challenges for the Integration of Toxicology with Epidemiology Data in Risk Assessment. *Food Chem. Toxicol* 2017, 103, 188–193. 10.1016/j.fct.2017.03.012. [PubMed: 28285934]